ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

argenx and UCB side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

argenxUCB
studies on the registry93581
open to participants now3024
phase 3 studies under way1620
reach primary completion within a year2114
programswith a study of their own in two years1416

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseargenxUCB
Phase 1

argenx: 7 of its 14 programs at phase 1

  1. Adimanebart SC - formulation Aphase 1
  2. ARGX-124phase 1
  3. empasiprubart SC AIphase 1
  4. ARGX-109phase 1
  5. ARGX-213phase 1

and 2 more — sign in to see them all

50%

UCB: 8 of its 16 programs at phase 1

  1. cizutamigphase 1
  2. Bimekizumab regimen 3 scphase 1
  3. Cizutamig will be dosed according to the protocol.phase 1
  4. CND261phase 1
  5. CND319phase 1

and 3 more — sign in to see them all

50%
Phase 2

argenx: 3 of its 14 programs at phase 2

  1. FB102phase 2
  2. Anti-MuSK Agonistic Monoclonal Antibody ARGX-119phase 2
  3. ARGX-121phase 2
21%

UCB: 3 of its 16 programs at phase 2

  1. galvokimigphase 2
  2. glovadalenphase 2
  3. donzakimigphase 2
19%
Phase 3

argenx: 2 of its 14 programs at phase 3

  1. empasiprubartphase 3
  2. adimanebartphase 3
14%

UCB: 4 of its 16 programs at phase 3

  1. bimekizumabphase 3
  2. zilucoplanphase 3
  3. dapirolizumab pegolphase 3
  4. Fenfluraminephase 3
25%
Approved, new studies

argenx: 2 of its 14 programs at approved, new studies

  1. efgartigimod alfaapproved, new study
  2. hyaluronidase (human recombinant)approved, new study
14%

UCB: 1 of its 16 programs at approved, new studies

  1. rozanolixizumabapproved, new study
6%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
argenx9 readouts · 1 phase 3

argenx, Nov ’26: 1 program whose next study reaches primary completion

  1. empasiprubartphase 3 · Nov 0 · NCT06284954

argenx, Dec ’26: 4 programs whose next study reaches primary completion

  1. adimanebartphase 3 · Dec 0 · NCT07673601
  2. Adimanebart SC - formulation Aphase 1 · Dec 0 · NCT07673601
  3. ARGX-124phase 1 · Dec 31 · NCT07377396
  4. FB102phase 2 · Dec 31 · NCT06905873
··

argenx, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. efgartigimod alfaapproved, new study · Mar 0 · NCT04833894
  2. empasiprubart SC AIphase 1 · Mar 0 · NCT07612020
  3. hyaluronidase (human recombinant)approved, new study · Mar 0 · NCT06655155
····

argenx, Aug ’27: 1 program whose next study reaches primary completion

  1. Anti-MuSK Agonistic Monoclonal Antibody ARGX-119phase 2 · Aug 24 · NCT06436742
··
UCB6 readouts · 2 phase 3·

UCB, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. UCB5285phase 1 · Dec 13 · NCT07286682
  2. bimekizumabphase 3 · Dec 21 · NCT06921850
··

UCB, Mar ’27: 1 program whose next study reaches primary completion

  1. zilucoplanphase 3 · Mar 23 · NCT06961747
·

UCB, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. rozanolixizumabapproved, new study · May 6 · NCT05063162
  2. galvokimigphase 2 · May 17 · NCT07277660

UCB, Jun ’27: 1 program whose next study reaches primary completion

  1. CND261phase 1 · Jun 1 · NCT07052032
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

argenx

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 2

UCB

New programs 1

  • UCB0159phase 1 · first study · Sep 24 · Psoriasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.

ConditionargenxUCB
Myasthenia Gravisboth · compare here

argenx in Myasthenia Gravis: 3 programs

  1. empasiprubartphase 3
  2. efgartigimod alfaapproved, new study
  3. hyaluronidase (human recombinant)approved, new study

Their studies: argenx’s studies of Myasthenia Gravis in search

UCB in Myasthenia Gravis: 3 programs

  1. zilucoplanphase 3
  2. cizutamigphase 1
  3. rozanolixizumabapproved, new study

Their studies: UCB’s studies of Myasthenia Gravis in search

Polyradiculoneuropathy, Chronic Inflammatory Demyelinatingboth · compare here

argenx in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 2 programs

  1. empasiprubartphase 3
  2. efgartigimod alfaapproved, new study

Their studies: argenx’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

UCB in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 1 program

  1. rozanolixizumabapproved, new study

Their studies: UCB’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

Multiple Myelomaboth · compare here

argenx in Multiple Myeloma: 1 program

  1. hyaluronidase (human recombinant)approved, new study

Their studies: argenx’s studies of Multiple Myeloma in search

UCB in Multiple Myeloma: 1 program

  1. cizutamigphase 1

Their studies: UCB’s studies of Multiple Myeloma in search

Purpura, Thrombocytopenic, Idiopathicboth · compare here

argenx in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. efgartigimod alfaapproved, new study

Their studies: argenx’s studies of Purpura, Thrombocytopenic, Idiopathic in search

UCB in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. rozanolixizumabapproved, new study

Their studies: UCB’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: argenx 1 of 14 · UCB 7 of 16 programs (8 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.